News Sentiment

BCDA sentiment intelligence

Biocardia Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.83 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

87/100 classification confidence.

Company focus 37

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-9.7% over one week, -14.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

BioCardia CEO Peter Altman buys $3,754 in company stock

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 87/100 classification
One-week reaction -9.7% Price reacting lower
Trend fit Trend inactive -14.6% over four weeks
Fair value -77.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 34
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 37
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 22
Market source 7
Investing.com 4
Investing.com Canada 4
Investing.com Nigeria 3
GlobeNewswire 2
simplywall.st 2
Finviz 1

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 8
Balance sheet 2
Analyst action 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 45
Investing.com Direct company coverage

BioCardia CEO Peter Altman buys $3,754 in company stock

BioCardia CEO Peter Altman recently purchased 4,300 shares of company common stock for a total of $3,754, with individual share prices ranging from $0.86 to $0.88. This insider buying occurred despite a recent decline in the stock's value, which has fallen 16.91% in the past week

Tone
Positive 62/100
Event
Market update
Published
16 Jul 2026 08:12
Source
Investing.com
Investing.com Canada Direct company coverage

BioCardia CEO Peter Altman buys $3,754 in company stock By Investing.com

BioCardia CEO Peter Altman recently purchased 4,300 shares of the company's common stock totaling $3,754, with individual transactions ranging from $0.86 to $0.88 per share. This insider buying follows a significant decline in the stock's value over the past year. The company is

Tone
Positive 64/100
Event
Market update
Published
15 Jul 2026 21:18
Source
Investing.com Canada
Investing.com Canada Direct company coverage

Form 4 Biocardia Inc For: 15 July By Investing.com

This article reports a Form 4 filing for Biocardia Inc. on July 15th, 2026. Form 4s disclose transactions made by company insiders. The article includes the stock symbol BCDA, which was up 9.23% at the time of publication, and is a brief notice published by Investing.com.

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 21:18
Source
Investing.com Canada
Stock Titan Direct company coverage

BioCardia (BCDA) CEO Peter Altman adds 4,300 shares in July 2026 buying

BioCardia, Inc. (BCDA) CEO Peter Altman purchased 4,300 shares of company common stock in open-market transactions in mid-July 2026. He bought 2,800 shares at $0.88 on July 14 and 1,500 shares at $0.86 on July 15, bringing his direct holdings to 368,385 shares. These transactions

Tone
Positive 66/100
Event
Market update
Published
15 Jul 2026 20:18
Source
Stock Titan
Investing.com Nigeria Direct company coverage

BioCardia president & CEO Peter Altman buys $7,175 in shares By Investing.com

BioCardia's President and CEO, Peter Altman, recently purchased $7,175 worth of company shares over three days, increasing his direct ownership to 369,485 shares. These transactions occurred as the stock, BCDA, traded between $0.90 and $0.97, reflecting a nearly 24% drop over the

Tone
Positive 65/100
Event
Market update
Published
11 Jul 2026 01:09
Source
Investing.com Nigeria
Investing.com Direct company coverage

BioCardia president & CEO Peter Altman buys $7,175 in shares

BioCardia's President and CEO, Peter Altman, recently purchased 7,500 shares of the company's stock for a total of $7,175, with prices ranging from $0.90 to $0.97 per share. This insider buying activity occurred as the stock's value decreased by nearly 24% over the previous week.

Tone
Positive 73/100
Event
Market update
Published
11 Jul 2026 00:39
Source
Investing.com
Investing.com Nigeria Direct company coverage

Form 4 Biocardia Inc For: 10 July By Investing.com

This article reports on a Form 4 filing for Biocardia Inc. on July 10, 2026. The brief entry includes the stock symbol BCDA, which was up 2.47% at the time of publication, and an Investing.com byline.

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 23:26
Source
Investing.com Nigeria
Stock Titan Direct company coverage

BioCardia (BCDA) CEO Peter Altman acquires 7,500 shares in open‑market buys

BioCardia, Inc. President and CEO, Peter Altman, recently acquired 7,500 shares of common stock through open-market purchases between July 8-10, 2026. These transactions, valued at approximately $7,175, involved shares bought at prices ranging from $0.90 to $0.97, increasing his

Tone
Positive 71/100
Event
Market update
Published
10 Jul 2026 22:39
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Biocardia Inc For: 7 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Biocardia Inc (BCDA) relating to activity on July 7th. The brief mention indicates that the company's stock experienced a -7.54% change. The content primarily serves as a placeholder for a financial filing update rath

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 23:44
Source
Investing.com Nigeria
Investing.com Direct company coverage

BioCardia CEO Peter Altman buys $5,208 in company stock

Peter Altman, CEO of BioCardia, Inc. (NASDAQ:BCDA), recently purchased 5,400 shares of the company's common stock for a total of $5,208. This insider buying comes after the stock has seen a 15% decline in the past week and is trading significantly below its 52-week high, although

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:39
Source
Investing.com
Investing.com Canada Direct company coverage

Form 4 Biocardia Inc For: 8 July By Investing.com

This article from Investing.com is a simple announcement of a Form 4 filing for Biocardia Inc. on July 8th. It includes the stock symbol BCDA, which was down 4.93% at the time of publication, and a Reuters copyright. The content primarily serves as a placeholder for financial rep

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 19:40
Source
Investing.com Canada
Stock Titan Direct company coverage

Insider buy: BioCardia (NASDAQ: BCDA) CEO adds 5,400 shares

BioCardia, Inc.'s President and CEO, Peter Altman, purchased 5,400 shares of common stock on the open market at a weighted average price of $0.9645 per share. This transaction, executed through multiple trades ranging from $0.92 to $1.05 per share, increases his direct holdings t

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

BioCardia (BCDA) CEO Altman has RSU tax shares withheld, receives new option grant

BioCardia President and CEO Peter Altman underwent routine equity compensation activities. On July 2, 2026, 54,606 shares were withheld by the company to cover tax obligations on vested RSUs, which was not a market sale. Subsequently, on July 6, 2026, Altman received a grant of s

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 12:40
Source
Stock Titan
Stock Titan Direct company coverage

BioCardia (BCDA) director Andrew Blank awarded 8,000 stock options at $1.20

BioCardia (BCDA) director Andrew Scott Blank was granted 8,000 stock options with an exercise price of $1.20 per share, expiring on July 6, 2036. These options will vest and become exercisable one year from the grant date, provided he remains a service provider. Following this gr

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 02:10
Source
Stock Titan
Stock Titan Direct company coverage

BioCardia (BCDA) director granted 8,000 stock options at $1.20

BioCardia, Inc. director Jim L. Allen was granted 8,000 stock options with an exercise price of $1.20 per share, as part of his compensation. These options will vest on the one-year anniversary of the grant date, provided he continues as a service provider. Following this award,

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 02:10
Source
Stock Titan
Stock Titan Direct company coverage

BioCardia (BCDA) SVP granted 29,442 options and has RSU shares withheld for taxes

BioCardia, Inc.'s Senior Vice President, Devices, Edward M. Gillis, was granted options for 29,442 shares of common stock at an exercise price of $1.20 per share, vesting monthly over four years starting August 6, 2026. Additionally, 17,269 common shares were withheld by BioCardi

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 02:10
Source
Stock Titan
Stock Titan Direct company coverage

BioCardia (BCDA) director Jay Moyes granted 8,000 stock options at $1.20

BioCardia, Inc. director Jay M. Moyes was granted 8,000 stock options with an exercise price of $1.20 per share, expiring on July 6, 2036. The options vest completely on the one-year anniversary of the grant date, provided Moyes remains a service provider. After this transaction,

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 02:10
Source
Stock Titan
Stock Titan Direct company coverage

BioCardia (BCDA) director Bill Facteau awarded 8,000 stock options at $1.20

BioCardia, Inc. director Bill Facteau has been granted 8,000 stock options with an exercise price of $1.20 per share, expiring on July 6, 2036. These options will vest completely on the one-year anniversary of the grant date, provided he remains a service provider. Following this

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 02:10
Source
Stock Titan
Stock Titan Direct company coverage

BioCardia (BCDA) director Marvin Slosman awarded 8,000 stock options at $1.20

BioCardia director Marvin Slosman was granted 8,000 stock options with an exercise price of $1.20 per share, expiring on July 6, 2036. These options will vest completely one year from the grant date, contingent on his continued service to the company. After this transaction, Slos

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 02:10
Source
Stock Titan
Stock Titan Direct company coverage

BioCardia (BCDA) CFO awarded 41,501 options; shares withheld for tax

BioCardia, Inc.'s CFO, David McClung, reported receiving 41,501 stock options with an exercise price of $1.20 per share, vesting monthly over 48 months from August 6, 2026. Additionally, 23,125 common shares were withheld by the company at $1.24 per share to cover tax obligations

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 02:10
Source
Stock Titan
Stock Titan Direct company coverage

BioCardia (BCDA) director receives 8,000 stock options exercisable at $1.20

BioCardia, Inc. director Simon H. Stertzer was granted 8,000 stock options with an exercise price of $1.20 per share, expiring on July 6, 2036. These options will vest and become exercisable one year from the grant date, provided Stertzer continues as a service provider. After th

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 02:10
Source
Stock Titan
Stock Titan Direct company coverage

BioCardia (BCDA) CEO Peter Altman granted 110,625 fully vested RSUs

BioCardia, Inc. CEO Peter Altman received an equity compensation award of 110,625 fully vested restricted stock units (RSUs) on June 29, 2026. These RSUs were granted as compensation in lieu of cash, valued at $1.20 per share, and increased his direct holdings to 411,191 shares.

Tone
Neutral 50/100
Event
Balance sheet
Published
01 Jul 2026 23:40
Source
Stock Titan
Stock Titan Direct company coverage

BioCardia (BCDA) SVP awarded 39,521 RSUs fully vesting on June 29, 2026

BioCardia, Inc. (BCDA) Senior Vice President of Devices, Edward M. Gillis, was granted 39,521 restricted stock units (RSUs) as compensation. These RSUs, valued at $1.20 per share, fully vested on June 29, 2026, increasing his direct holdings to 71,395 shares of common stock. This

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 23:40
Source
Stock Titan
Stock Titan Direct company coverage

BioCardia (BCDA) CFO granted 60,483 RSUs as stock compensation

BioCardia Inc.'s Chief Financial Officer, David McClung, was granted 60,483 restricted stock units (RSUs) as compensation, which fully vested on June 29, 2026. This award, valued at $1.20 per share, increased his direct holdings to 137,370 shares. The transaction is categorized a

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 23:40
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Biocardia Inc For: 1 July By Investing.com

Investing.com reports on a Form 4 SEC filing by Biocardia Inc. for July 1st. The article provides the filing date and includes a general market overview with various indices, commodities, and stock performances.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 19:40
Source
Investing.com Canada
Finviz Direct company coverage

BCDA - BioCardia Inc Latest SEC Filings

This article provides a detailed financial overview of BioCardia Inc. (BCDA), including its latest stock performance, key financial metrics like market cap, income, and sales, and various valuation ratios. It also lists insider and institutional ownership, analyst recommendations

Tone
Neutral 50/100
Event
Analyst action
Published
29 Jun 2026 15:09
Source
Finviz